We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study to Evaluate Subcutaneously Administered rAvPAL-PEG in Patients With Phenylketonuria for 24 Weeks

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01560286
Recruitment Status : Completed
First Posted : March 22, 2012
Results First Posted : February 27, 2019
Last Update Posted : August 6, 2019
Information provided by (Responsible Party):
BioMarin Pharmaceutical

Brief Summary:
The primary objective of the study is to evaluate the effect of dosing regimens of multiple subcutaneous (SC) doses of rAvPAL-PEG to induce an early and sustained Phe reduction while decreasing the frequency and severity of hypersensitivity reactions in patients with PKU.

Condition or disease Intervention/treatment Phase
Phenylketonuria Biological: BMN 165 (rAvPAL-PEG) Phase 2

Detailed Description:
The primary rationale for this study is to define an optimal rAvPAL-PEG dose regimen by establishing the therapeutic effect within the shortest time possible time for induction, titration and maintenance phases while reducing the severity and frequency of hypersensitivity reactions that may lead to dose interruptions. It is hypothesized that these goals can be achieved by keeping rAvPAL-PEG doses low when anti-PEG IgM response is predicted to be high and titrating to an efficacious dose once the IgG response to PAL has developed. Further investigation is needed to determine how early and quickly patients can titrate safely to lower blood Phe; therefore, this protocol proposes to assess two Groups using an induction/titration and maintenance schedule with an aim towards establishing the therapeutic effect safety within an optimal period of time.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multi-center, Open-label, Dose-finding Study to Evaluate Safety, Efficacy and Tolerability of Subcutaneously (SC) Administered rAvPAL-PEG in Patients With PKU for 24 Weeks
Study Start Date : May 2012
Actual Primary Completion Date : September 2013
Actual Study Completion Date : July 2015

Arm Intervention/treatment
Experimental: Group 1
4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose
Biological: BMN 165 (rAvPAL-PEG)
Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
Other Name: Recombinant Anabaena variabilis phenylalanine ammonia lyase

Primary Outcome Measures :
  1. Blood Phenylalanine Concentration [ Time Frame: Baseline, Week 24 ]
    All patients will have their plasma Phenylalanine (Phe) assessed. Please note that "Pharmacokinetics Sub-study" was not performed, and thus no results are available.

Secondary Outcome Measures :
  1. Number of Participants With Study Drug Related Adverse Events [ Time Frame: Minimum Weekly Assessment of Injection Sites, Vital Signs and Adverse Events. Other Safety Assessments will be performed at other intervals (below): ]
  2. Percentage of Participants With Positive Anti-PAL Immunoglobulin G [IgG] [ Time Frame: Baseline, Week 24 ]
    Antibody Positivity

  3. Trough Concentration of BMN 165 [ Time Frame: Week 1, Week 24 ]
    PK assessment from pre-dose blood draw.

  4. Percentage of Participants With Positive Anti-PEG IgG [ Time Frame: Baseline, Week 24 ]
    Antibody Positivity

  5. Percentage of Participants With Positive PAL-IgM [ Time Frame: Baseline, Week 24 ]
    Antibody Positivity

  6. Percentage of Participants With Positive Anti-PEG-IgM [ Time Frame: Baseline, Week 24 ]
    Antibody positivity

  7. Percentage of Participants With Positive Neutralizing Antibodies [Nab] [ Time Frame: Baseline, Week 24 ]
    Antibody positivity

  8. Percentage of Participants With Positive Anti-PAL-IgE Antibodies [ Time Frame: Baseline, Week 24 ]
    Antibody positivity

  9. Percentage of Participants With Positive Anti-PAL-PEG IgE Antibodies [ Time Frame: Baseline, Week 24 ]
    Antibody positivity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. A diagnosis of PKU, with the following:

    • Current blood Phe concentration of ≥ 600 µmol/L at Screening.
    • Average blood Phe concentration of ≥ 600 µmol/L over the past 6 months, using available data.
    • Naïve to prior treatment with rAvPAL-PEG.
  2. Evidence that the patient is a non responder to Kuvan® treatment (ie, 4 weeks of treatment with 20 mg/kg/day of Kuvan, insufficient response per investigator determination, unsuitable for Kuvan® per Investigator determination, and treatment end date ≥ 2 days prior to Day 1 [ie, first dose]). Patients who have had a previous response to Kuvan® treatment but are not currently taking Kuvan® because of noncompliance and have been off treatment for ≥ 4 months prior to Screening are eligible for participation.
  3. Willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to any research-related procedures. In the case of participants under the age of 18 or participants who have been deemed mentally unable to provide informed consent, a parent or legal guardian may provide written informed consent (and, if required, the patient will provide written assent).
  4. Willing and able to comply with all study procedures.
  5. Between the ages of 16 and 70 years, inclusive.
  6. Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
  7. Sexually active patients must be willing to use an acceptable method of contraception while participating in the study.
  8. Maintained a stable diet with no significant modifications during the 4 weeks preceding the administration of study drug and willing to continue with the diet while on study so as to avoid potential variability of response due to variations in dietary intake.
  9. In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and electrocardiogram (ECG) at Screening.

Exclusion Criteria:

  1. Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  2. Use of any medication that is intended to treat PKU, including use of large amino acids, within 2 days prior to the administration of study drug.
  3. Use or planned use of any injectable drugs containing PEG (other than rAvPAL-PEG), including Depo-Provera, within 3 months prior to Screening and during study participation.
  4. A prior reaction that included systemic symptoms (eg, respiratory or gastrointestinal problems, hypotension, angioedema, anaphylaxis) to a PEG containing product. Patients with a prior systemic reaction of generalized rash may be eligible for participation per the discretion of the Principal Investigator in consultation with the Sponsor's Medical Officer.
  5. Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.
  6. Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
  7. Any condition that, in the view of the PI, places the patient at high risk of poor treatment compliance or of not completing the study.
  8. Alanine aminotransferase (ALT) concentration > 2 times the upper limit of normal.
  9. Creatinine > 1.5 times the upper limit of normal.
  10. A positive test for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen and hepatitis C antibody.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01560286

Layout table for location information
United States, Colorado
The Children's Hospital
Aurora, Colorado, United States, 80048
United States, Florida
University of Florida, Gainesville
Gainesville, Florida, United States, 32610
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
United States, Nebraska
Nebraska Medical Center
Omaha, Nebraska, United States, 68198
United States, New York
Albany Medical Center
Albany, New York, United States, 12208
United States, Utah
University of Utah Hospital
Salt Lake City, Utah, United States, 84132
Sponsors and Collaborators
BioMarin Pharmaceutical
Layout table for investigator information
Study Director: Debra Lounsbury BioMarin Pharmaceutical
Layout table for additonal information
Responsible Party: BioMarin Pharmaceutical
ClinicalTrials.gov Identifier: NCT01560286    
Other Study ID Numbers: 165-205
First Posted: March 22, 2012    Key Record Dates
Results First Posted: February 27, 2019
Last Update Posted: August 6, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by BioMarin Pharmaceutical:
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases